Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...
although Amgen has also reported positive pivotal trial results in KRAS G12C-mutated colorectal cancer for Lumakras in combination with its own EGFR drug Vectibix (panitumumab). The CRC approval ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Lumakras with Vectibix demonstrated superior progression-free survival and objective response rate in KRAS G12C-mutated metastatic colorectal cancer. Datroway improved progression-free survival and ...
This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." The CodeBreaK 300 clinical trial compared ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback